Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers.

European journal of pharmacology - 19 Dec 2005

Siest Gérard, Marteau Jean-Brice, Maumus Sandy, Berrahmoune Hind, Jeannesson Elise, Samara Anastasia, Batt Anne-Marie, Visvikis-Siest Sophie

Abstract excerpt

Personalized medicine is based on a better knowledge of biological variability, considering the important part due to genetics. When trying to identify involved genes and their products in differential cardiovascular drug responses, a five-step strategy is to be followed: 1) Pharmacokinetic-related genes and phenotypes (2) Pharmacodynamic targets, genes and products (3) Cardiovascular diseases and risks depending...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cardiovascular Agents
Share to Cardiovascular Diseases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Genotype

Share to Models, Biological

Share to Pharmacogenetics

Share to Phenotype

Share to Proteomics

Source

Identifiers

PMID: 16316654
DOI: 10.1016/j.ejphar.2005.10.011

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Pharmacogenomics and cardiovascular drugs: need for integrated biological system with phenotypes and proteomic markers.PMID 16316654Read ↗

Cardiovascular pharmacogenetics of antihypertensive and lipid- lowering therapies.Semantic proximity Read ↗

Genetics and personalized medicine--a role in statin therapy?Semantic proximity Read ↗

Pharmacogenomics of drugs affecting the cardiovascular system.Semantic proximity Read ↗

Genomics and the prospects of existing and emerging therapeutics for cardiovascular diseases.Semantic proximity Read ↗

Towards a More Personalized Treatment of Dyslipidemias to Prevent Cardiovascular Disease.Semantic proximity Read ↗

[Pharmacogenetics--pathway to individualized antihypertensive pharmacotherapy].Semantic proximity Read ↗

When the same treatment has different response: The role of pharmacogenomics in statin therapySemantic proximity Read ↗

Cardiovascular Pharmacokinetics, Pharmacodynamics, and Pharmacogenomics for the Clinical Practitioner.Semantic proximity Read ↗

Prognostic Implications of Genetics in Cardiovascular Disease.Semantic proximity Read ↗

Recent developments and future directions for the use of pharmacogenomics in cardiovascular disease treatments.Semantic proximity Read ↗

[Pharmacogenetics--new perspectives in the treatment of cardiovascular diseases].Semantic proximity Read ↗

Pharmacogenomics of primary hypertension--the lessons from the past to look toward the future.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.